Peptide Comparison

AdipotidevsSemaglutide

A targeted fat-destroying peptide that works like a smart missile, cutting off blood supply to fat cells and causing rapid weight loss in primate studies.

The revolutionary once-weekly GLP-1 medication that helps your body feel full faster and longer, leading to significant weight loss while also protecting your heart—FDA approved and backed by some of the largest clinical trials in obesity medicine history.

Weight ManagementWeight Management

At a Glance

Quick
comparison

Dose Range

Adipotide

0.1–0.43 mg/kg

Semaglutide

0.25–2.4 mg

Frequency

Adipotide

Once daily

Semaglutide

Once weekly

Administration

Adipotide

Subcutaneous injection

Semaglutide

Subcutaneous injection

Cycle Length

Adipotide

4-6 weeks

Semaglutide

Ongoing/indefinite

Onset Speed

Adipotide

Moderate (1-2 weeks)

Semaglutide

Moderate (1-2 weeks)

Evidence Level

Adipotide

Strong preclinical (extensive animal studies)

Semaglutide

Strong human trials (Phase 3 or FDA approved)

Efficacy

Benefit
ratings

Adipotide
Semaglutide

Fat Elimination

Adipotide95%
Semaglutide0%

Metabolic Improvement

Adipotide88%
Semaglutide0%

Speed of Results

Adipotide92%
Semaglutide0%

Weight Loss

Adipotide0%
Semaglutide98%

Appetite Control

Adipotide0%
Semaglutide95%

Heart Protection

Adipotide0%
Semaglutide92%

Technical Data

Compound
specifications

Adipotide

Molecular Formula

C111H206N36O28S2

Molecular Weight

2611.41 g/mol

Half-Life

~24 hours

Bioavailability

High (subcutaneous injection)

CAS Number

859216-15-2

Semaglutide

Molecular Formula

C187H291N45O59

Molecular Weight

4113.58 g/mol

Half-Life

Approximately 7 days (168 hours)

Bioavailability

89% (subcutaneous); 0.4-1% (oral, with absorption enhancer)

CAS Number

910463-68-2

Protocols

Dosing
tiers

Adipotide

starting

0.1 mg/kg

Once daily

1-2 weeks

Begin with the lowest effective dose to assess tolerance and monitor kidney function. This cautious approach helps identify any sensitivity before progressing.

standard

0.25 mg/kg

Once daily

2-4 weeks

This intermediate dose showed good efficacy with manageable side effects in primate studies. Regular monitoring of renal markers is essential.

advanced

0.43 mg/kg

Once daily

4 weeks maximum

The optimal therapeutic dose identified in primate studies. Produced average 11% body weight loss in 4 weeks. Requires close kidney monitoring and adequate hydration.

Semaglutide

starting

0.25 mg

Once weekly

4 weeks

This starting dose is designed to let your body adjust to the medication and minimize nausea. You probably won't see much weight loss yet—that's normal. This phase is all about getting your GI system used to the medication.

standard

0.5-1.0 mg

Once weekly

8+ weeks at each dose

After 4 weeks at 0.25mg, increase to 0.5mg. After another 4 weeks, move to 1.0mg. This gradual approach significantly reduces nausea and vomiting. Most people start seeing meaningful weight loss at the 0.5-1.0mg doses.

advanced

1.7-2.4 mg

Once weekly

Ongoing/maintenance

The 2.4mg dose (Wegovy) is the FDA-approved dose for chronic weight management. Continue increasing by 0.5mg increments every 4 weeks until reaching 2.4mg. This is where the most significant weight loss occurs—averaging 15% or more of body weight in trials.

Applications

Best
suited for

Adipotide

Targeted White Fat Reduction

Adipotide specifically seeks out and destroys the blood vessels feeding white adipose tissue. Unlike diet or exercise that shrink fat cells, this peptide actually eliminates fat tissue by cutting off its blood supply - a completely unique mechanism.

Stubborn Fat Deposits

Because it targets the vasculature of fat tissue directly, Adipotide may be particularly effective for stubborn fat deposits that resist traditional methods. The peptide homes in on prohibitin receptors found specifically on blood vessels supplying fat tissue.

Improving Insulin Resistance

Primate studies showed remarkable improvements in insulin sensitivity - treated monkeys used about 50% less insulin after treatment. This makes it interesting for research into obesity-related metabolic dysfunction.

Research Applications

As a pioneering vascular-targeting peptide, Adipotide represents a new class of potential therapeutics. Its unique mechanism of targeting specific tissue vasculature has implications beyond obesity research.

Semaglutide

People with Obesity Seeking Significant Weight Loss

If your BMI is 30 or higher (or 27+ with weight-related health conditions), semaglutide is currently one of the most effective non-surgical weight loss options available. Clinical trials show average weight loss of 15% of body weight—that's 30+ pounds for someone starting at 200 pounds.

Those Who've Struggled with Diet and Exercise Alone

Semaglutide works by changing the biological signals that drive hunger and cravings. If you've tried to lose weight through willpower alone and found yourself constantly battling hunger, this medication addresses that underlying biology rather than just telling you to eat less.

People with Type 2 Diabetes Needing Better Control

Originally developed for diabetes, semaglutide excellently controls blood sugar while also promoting weight loss—addressing two major health concerns simultaneously. It can often allow people to reduce or eliminate other diabetes medications.

Individuals at High Cardiovascular Risk

The SELECT trial proved that semaglutide reduces heart attacks, strokes, and cardiovascular death by 20% in people with obesity and existing heart disease—even without diabetes. It's one of the few weight loss medications proven to improve hard cardiovascular outcomes.

Safety Profile

Side
effects

Adipotide

Common

  • Elevated Serum Creatinine
  • Proteinuria
  • Glucosuria
  • Reduced Appetite

Uncommon

  • Mild Dehydration
  • Injection Site Reactions

Serious

  • Renal Tubular Dysfunction

Semaglutide

Common

  • Nausea
  • Constipation or Diarrhea
  • Decreased Appetite
  • Vomiting

Uncommon

  • Gallbladder Problems
  • Hair Loss (Telogen Effluvium)

Serious

  • Pancreatitis
  • Thyroid Tumors (Theoretical Risk)

Research Status

Safety
& evidence

Adipotide

Evidence Level

Strong preclinical (extensive animal studies)

FDA Status

Research compound

Safety Overview

Adipotide has been extensively studied in mice, rats, and three species of primates with consistent results. The primary safety concern is dose-dependent kidney effects, which were reversible upon stopping treatment in all studies. No cardiovascular, neurological, or hepatic adverse events were observed. The compound shows remarkable selectivity - lean animals given the same doses experienced no weight loss, suggesting it specifically targets excess fat tissue.

Contraindications

  • xKidney disease or impaired renal function
  • xPregnancy or breastfeeding
  • xActive infections or compromised immune system
  • xHistory of severe allergic reactions to peptides
  • xDehydration or conditions affecting fluid balance

Semaglutide

Evidence Level

Strong human trials (Phase 3 or FDA approved)

FDA Status

FDA approved for this use

Safety Overview

Semaglutide has been studied in over 20,000 participants across multiple large clinical trials, making it one of the most thoroughly researched weight loss medications available. The FDA approved it after rigorous review of safety data. While GI side effects are common (especially early on), serious side effects are rare. The SELECT trial showed it actually reduces cardiovascular events, adding a safety benefit beyond just weight loss.

Contraindications

  • xPersonal or family history of medullary thyroid carcinoma (MTC)
  • xMultiple Endocrine Neoplasia syndrome type 2 (MEN2)
  • xHistory of serious allergic reaction to semaglutide
  • xCurrent or recent pancreatitis
  • xPregnancy or planning to become pregnant

Decision Guide

Which is
right for you?

Choose Adipotide if...

  • Targeted fat reduction
  • Improving insulin resistance
  • Reducing stubborn white adipose tissue
  • Research into vascular-targeted therapies

Choose Semaglutide if...

  • Significant weight loss
  • Long-term weight management
  • Cardiovascular risk reduction
  • Blood sugar control
Peptide ProAdipotide vs Semaglutide — Peptide Comparison | Peptide Initiative